Clinical trial · Observational
Anti-obesity Pharmacotherapy and Inflammation
Pilot Study of the Effect of Weight Loss by Pharmacotherapy on Chronic Pro-tumor Inflammatory Cells
NCT05756764CI-TRIAL-00094812active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Obesity | — | UNRESOLVED | — |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diethylpropion | Drug | — | UNRESOLVED |
| Liraglutide | Drug | — | UNRESOLVED |
| Naltrexone/Bupropion | Drug | — | UNRESOLVED |
| Phentermine | Drug | — | UNRESOLVED |
| Phentermine-Topiramate combination | Drug | — | UNRESOLVED |
| Semaglutide | Drug | — | UNRESOLVED |
| Tirzepatide | Drug | — | UNRESOLVED |
| Topiramate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with obesity on pharmacotherapy
- description
- Before initiation of pharmacotherapy (as part of the standard-of-care treatment) and 6 months after initiated medication
- interventionNames
- Drug: Semaglutide
- Drug: Phentermine-Topiramate combination
- Drug: Phentermine
- Drug: Tirzepatide
- Drug: Topiramate
- Drug: Diethylpropion
- Drug: Naltrexone/Bupropion
- Drug: Liraglutide
Primary outcomes (3)
- measure
- weight loss
- timeFrame
- baseline and 24 weeks
- description
- Weight Loss Percentage (Pounds lost divided by starting weight (in pounds) multiplied by 100)
- measure
- MDSC in peripheral blood
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Body mass index (BMI): over 30 kg/m2 * Age: 35 to 60 years old Exclusion Criteria: * Taking medications with anti-inflammatory properties like glucocorticoids, prednisone, or non-steroidal anti-inflammatory medications, such as aspirin or Motrin Subjects on medications for long-term weight management such as phentermine-topiramate (Qsymia), orlistat (Xenical), naltrexone-bupropion (Contrave), and the glucagon-like peptide-1 receptor agonists such as liraglutide (Saxenda), and semaglutide (Wegovy). * Prior history of cancer * Having any clinical symptoms of systemic inflammation, acute infections such as Coronavirus disease 2019, or chronic diseases such as cancer, tuberculosis, autoimmune disease, and AIDS * An adult unable to consent * Prisoner * Pregnancy or breastfeeding women
References
Publications (0)
Data not yet available
No reference posted for this study.